accountcutting research spending and eliminating thousands of jobs. In March it closed a $3.6 billion acquisition of King Pharmaceuticals Inc., a pain drug maker based in Bristol, Tenn. Pfizer planned to buy back $5 billion in stock in 2011, not including...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer selling Capsugel unit to KKR for $2.38B
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account